Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 7.4 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 6.7 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 7.5 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 6.7 20 to 24 years . . . . . . . . . . . . . . . . . . . . . . ....

This paper compares the finite sample performance of the canonical correlation regression estimator (CCR) and Stock and Watson's (A simple estimator of cointegration vectors in higher order integrated systems, Econometrica, 1993, 61(4), 783-820) dynamic ordinary least squares estimator (DOLS) using the models proposed by Inder (Journal of Econometrics, 1993, 57, 53-68). The CCR estimator shows ...

8.7.6.1 Electromigration in Encapsulated Metal Line 52 8.7.6.2 Basic Electromigration Characteristics 53 8.7.6.3 Balancing Electron Wind with Stress Gradient 55 8.7.6.4 No-Voiding Condition for Encapsulated Line 56 8.7.6.5 Saturated Void Volume (SVV) 57 8.7.6.6 Experimental Determination of Z ; DaðT T0Þ; B; and D 58 8.7.6.7 No-Extrusion Condition for Encapsulated Line 59 8.7.6.8 The Immortal In...

....................................................................................................... 46 Abbreviations ............................................................................................... 46 Introduction .................................................................................................. 47 Materials and Methods ...........................................

The prevalence of cervical human papillomavirus (HPV) in South African women (n = 1,073) increased from 20.4% (173/848) in women with normal cytology to 41.7% (48/115) in women with atypical squamous cells of undetermined significance, 70.2% (40/57) in women with low-grade squamous intraepithelial lesions, and 83% (44/53) in women with high-grade squamous intraepithelial lesions (HSILs). HPV ty...

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 8.3 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 8.6 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 8.1 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 5.3 20 to 24 years . . . . . . . . . . . . . . . . . . . . . . ....

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 4.8 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 6.7 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 7.0 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 5.5 20 to 24 years . . . . . . . . . . . . . . . . . . . . . . ....